SageView Advisory Group’s Taysha Gene Therapies TSHA Stock Holding History

SageView Advisory Group’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-49	Closed	-$270	–	2289
2025 Q4	$270	Buy	+49	New	+$238	﹤0.01%	2499

Other funds holding TSHA

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SageView Advisory Group's TSHA Position: Q1 2026 in Review

SageView Advisory Group sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 49 shares — an estimated $270 sold.

SageView Advisory Group first reported a position in TSHA in Q4 2025 and held it in 1 quarter. The position peaked at $270 in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

SageView Advisory Group reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 49 Taysha Gene Therapies shares in Q1 2026, an estimated $270.
SageView Advisory Group first reported a position in Taysha Gene Therapies in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's Taysha Gene Therapies position peaked at $270 in Q4 2025.
191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.